MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Placebo response in Parkinson’s disease (PD) is predicted by expression levels of a specific brain network

    J. Barbero, C. Tang, A. Vo, Y. Ma, S. Peng, B. Brakedal, C. Dölle, N. Brekke, C. Tzoulis, D. Eidelberg (Manhasset, USA)

    Objective: To determine whether baseline expression levels for the previously validated sham surgery-related metabolic pattern (SSRP) can be used to predict the magnitude of the…
  • 2023 International Congress

    Neuropsychological and quality of life outcome comparison after awake and asleep pallidal deep brain stimulation (DBS) surgery for Parkinson’s disease

    A. Tröster, A. Novak, S. Russell, K. Hanson (Phoenix, USA)

    Objective: To compare cognitive, psychiatric and quality of life (QoL) outcomes after awake and asleep bilateral pallidal (GPi) deep brain stimulation (DBS). Background: Prior studies…
  • 2023 International Congress

    SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation

    E. Gülke, M. Höfs, H. Pinnschmidt, A. Gulberti, C. Moll, U. Hidding, C. Buhmann, M. Heise, W. Hamel, M. Pötter-Nerger (Hamburg, Germany)

    Objective: This monocentric, randomised, blind study is designed to evaluate the effect of safinamide on motor and neuropsychiatric symptoms in the 3 month perioperative period…
  • 2023 International Congress

    Real-life monitoring of Parkinson’s disease tremor: does the non-tremor subtype really exist?

    R. Terranova, L. Evers, D. Soriano, Y. Raykov, M. Little, H. Cagnan, B. Bloem, R. Helmich (Catania, Italy)

    Objective: To quantify daily-life tremor in Parkinson’s disease (PD) using a smartwatch containing a three-axis accelerometer and gyroscope. Background: Objective and continuous evaluation of PD…
  • 2023 International Congress

    Altered brain energetics in Parkinson’s Disease: a multimodal neuroimaging study

    C. Bevington, J-C. Cheng, R. Jayde-Williams, B. Pike, J. Mckenzie, A. Stoessl, V. Sossi (Vancouver, Canada)

    Objective: To investigate patterns of altered brain energetics in Parkinson’s disease (PD). Background: Alterations in mitochondrial function, related to brain energetics, may play an important…
  • 2023 International Congress

    Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial

    J. Suescun, T. Ellmore, C. Adams, V. Thyne, E. Tharp, S. Chandra, C. Green, R. Shastri, J. Saltarrelli, M. Schiess (Houston, USA)

    Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…
  • 2023 International Congress

    Analysis of the relationship between acoustic measures and VHI score

    Y. Manor, Y. Kochetkov, Y. Hauptman, D. Shpunt, A. Zait, T. Gurevich (Tel Aviv, Israel)

    Objective: To examine whether there is a relationship between acoustic measurements extracted from audio recordings of sustained vowel /a/ of PWP and their VHI scores.…
  • 2023 International Congress

    Comparison in the disability level according to WHODAS 2 between people living with Early and Late Onset Parkinson’s Disease

    M E. Pimentel Piemonte, K. Costa Nobrega, I. Silva Nascimento, B. Antunes Souza, I. Carneiro Barone, G. Checchio, V. Pereira Ponciano, C. Cerveira Paula, A. Nunes Possani, N. Cardos Penha (Sao Paulo, Brazil)

    Objective: To compare disability levels according to WHODAS-2 between people living with EOPD and people living with LOPD. Background: Although Parkinson's disease (PD) is more…
  • 2023 International Congress

    An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials

    R. Freeman, I. Biaggioni, L. Norcliffe-Kaufmann, T. Guerin, R. Vickery, L. Manzanares, V. Iodice, M. Rudzińska-Bar, M. Pellecchia, H. Kaufmann (Boston, USA)

    Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…
  • 2023 International Congress

    Association of real-world wearable mobility measures with Parkinson’s disease severity and disease progression

    A. Mirelman, J. Volkov, A. Solomon, E. Gazit, A. Nieuwboer, S. Del Din, L. Rochester, L. Avanzino, E. Pelosin, B. Bloem, U. Della Croce, A. Cereatti, A. Thaler, J. Shirvan, J. Cedarbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

    Objective: To identify real-world mobility measures that are most reflective of PD severity and to assess their sensitivity to changes over time, as compared to…
  • « Previous Page
  • 1
  • …
  • 121
  • 122
  • 123
  • 124
  • 125
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley